Compositions comprising azelastine and methods of use thereof
View Patent ↗The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions into the oral cavity, upon intranasal or ocular administration of the compositions. Especially effective excipients used in the compositions of the present invention are hypromellose as a viscosity modifier and sucralose as a taste-masking agent. The invention also provides methods of treating or preventing certain disorders, or symptomatic relief therefrom, by administering the compositions of the invention to a patient, e.g., for the symptomatic relief of allergic rhinitis, non-allergic vasomotor rhinitis, allergic conjunctivitis, as well as other disorders.
1. An intranasal pharmaceutical product, comprising a liquid pharmaceutical composition comprising: (i) from about 0.05% to about 0.5% (w/v) azelastine hydrochloride, (ii) from about 0.01% to about 1.0% (w/v) fluticasone propionate, and (iii) from about 0.1% to about 0.5% (w/v) sucralose,
wherein the composition in the intranasal pharmaceutical product is formulated for intranasal administration in a human.
2. The intranasal pharmaceutical product of claim 1 , further comprising one or more additional active agents selected from the group consisting of one or more decongestants, one or more antihistamines, one or more non-steroidal anti-inflammatory agents and one or more leukotriene antagonists.
3. The intranasal pharmaceutical product of claim 1 , wherein said azelastine hydrochloride is present in said composition at a concentration of from about 0.125% to about 0.15% (w/v).
4. The intranasal pharmaceutical product of claim 1 , wherein said azelastine hydrochloride is present in said composition at a concentration of from about 0.05% to about 0.15% (w/v).
5. The intranasal pharmaceutical product of claim 1 , wherein said liquid pharmaceutical composition is contained within an intranasal delivery system.
6. The intranasal pharmaceutical product of claim 5 , wherein said intranasal delivery system comprises a bottle and a pump.
7. The intranasal pharmaceutical product of claim 6 , wherein pump is a metered multi-dose pump.
8. The intranasal pharmaceutical product of claim 1 , wherein said liquid pharmaceutical composition is in the form of a nasal spray.
9. The intranasal pharmaceutical product of claim 1 , wherein said liquid pharmaceutical composition is in the form of nasal drops.
10. The intranasal pharmaceutical product of claim 1 , wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.07 to about 0.15 ml per spray.
11. The intranasal pharmaceutical product of claim 10 , wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.14 ml per spray.
12. The intranasal pharmaceutical product of claim 1 , wherein said sucralose in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 0.2% (w/v).
13. The intranasal pharmaceutical product of claim 1 , wherein said sucralose in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 0.15% (w/v).
14. The intranasal pharmaceutical product of claim 1 , wherein said sucralose in said liquid pharmaceutical composition is present at a concentration of about 0.15% (w/v).
15. The intranasal pharmaceutical product of claim 1 , wherein said azelastine hydrochloride in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 0.15% (w/v).
16. The intranasal pharmaceutical product of claim 1 , wherein said liquid pharmaceutical composition further comprises sorbitol.
17. The intranasal pharmaceutical product of claim 16 , wherein said sorbitol in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 10% (w/v) sorbitol 70%.
18. The intranasal pharmaceutical product of claim 16 , wherein said sorbitol in said liquid pharmaceutical composition is present at a concentration of about 6.4% (w/v) sorbitol 70%.
19. A method of treating allergic rhinitis, non-allergic vasomotor rhinitis or allergic conjunctivitis in a human suffering from or predisposed thereto, comprising intranasally administering to said human an effective amount of the intranasal pharmaceutical product of claim 1 .
20. The method of claim 19 , wherein said liquid pharmaceutical composition is contained within an intranasal delivery system.
21. The method of claim 20 , wherein said liquid pharmaceutical composition is in the form of a nasal spray.
22. The method of claim 19 , wherein said liquid pharmaceutical composition further comprises sorbitol.
23. The method of claim 19 , wherein said liquid pharmaceutical composition is contained within an intranasal delivery system.
24. The method of claim 23 , wherein said intranasal delivery system comprises a bottle and a pump.
25. The method of claim 24 , wherein said pump is a metered multi-dose pump.
26. The method of claim 19 , wherein said liquid pharmaceutical composition is in the form of nasal drops.
27. The method of claim 19 , wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.07 to about 0.15 ml per spray.
28. The method of claim 27 , wherein said liquid pharmaceutical composition is formulated to intranasally deliver a volume of said composition of about 0.14 ml per spray.
29. The method of claim 19 , wherein said sucralose in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 0.2% (w/v).
30. The method of claim 19 , wherein said sucralose in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 0.15% (w/v).
31. The method of claim 19 , wherein said sucralose in said liquid pharmaceutical composition is present at a concentration of about 0.15% (w/v).
32. The method of claim 19 , wherein said azelastine hydrochloride in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 0.15% (w/v).
33. The method of claim 19 , wherein said liquid pharmaceutical composition further comprises sorbitol.
34. The method of claim 33 , wherein said sorbitol in said liquid pharmaceutical composition is present at a concentration of about 0.1% to about 10% (w/v) sorbitol 70%.
35. The method of claim 33 , wherein said sorbitol in said liquid pharmaceutical composition is present at a concentration of about 6.4% (w/v) sorbitol 70%.